"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead

Outcomes of Hypofractionated Stereotactic Radiotherapy for Intracranial Meningioma: a Systematic Review of the Literature


Abstract

Purpose

The availability of image guidance and intensity modulation has led to the increasing use of hypofractionated stereotactic radiotherapy (hSRT) as an alternative to conventionally fractionated radiotherapy or radiosurgery for intracranial meningioma (ICM). As the safety and efficacy of this approach is not well characterized, we conducted a systematic review of the literature to assess the clinical outcomes of hSRT in the setting of ICM.

 

Methods

A systematic review of Medline and EMBASE databases was performed following the PRISMA guidelines. Included studies were retrospective or prospective series that 1) examined an ICM population of ≥ 10 patients, 2) delivered >1 fraction of photon hSRT (≥ 2.5 Gy per fraction), 3) used a LINAC-based platform, Cyberknife (CK) or multisession Gammaknife, 4) reported on clinical outcomes, and 5) had a median follow-up of ≥ 2 years. Descriptive statistics were generated for included studies.

 

Results

1480 initial studies, 14 met eligibility criteria for inclusion, reporting on 630 patients (age range 18-90) treated for 638 tumors. Primary RT was delivered in 37% of patients, 36% had radiation following surgery, and surgical details were unavailable in 27%. Of all tumors, 66% were located in the skull base and 8% involving optic structures. Treatment platforms included LINAC-based hSRT (57%) or CK (43%). Total dose ranged from 15-45Gy in 2-15 fractions and was prescribed to a median isodose line of 80%. The most common fractionation reported was 25/5. In 474 tumors assessed for radiologic response (median follow-up = 24.5-57.5 months), 78% remained stable, 18% decreased in size and 4% increased in size. Of 327 patients who were symptomatic prior to treatment, 17% had complete resolution, 41% had improvement, 36% had stability and 6% had deterioration post treatment. Crude local control (LC) was 90-100% as reported in 10 studies. Overall, the median late toxicity rate was 10% (range=0-21%). The median late toxicity rates for tumors involving the skull base and optic structures were 5% (range=0-21%) and 9% (range=8-10%) respectively. Most common significant late toxicities were new decrease in vision (n=8) and new cranial neuropathy (n=11).

 

Conclusions

While the available literature of hSRT for treatment of ICM suggests that local control and toxicity profiles are comparable to other radiotherapy approaches, confirmation in larger patient cohorts with longer follow-up is required.

Poster
non-peer-reviewed

Outcomes of Hypofractionated Stereotactic Radiotherapy for Intracranial Meningioma: a Systematic Review of the Literature


Author Information

Timothy K. Nguyen Corresponding Author

Department of Radiation Oncology, London Regional Cancer Program, Western University, London, Ontario, CA

Eric K. Nguyen

Department of Radiation Oncology, Juravinski Cancer Center, Hamilton, Canada, Juravinski Cancer Center, Hamilton, Canada

Hanbo Chen

Radiation Oncology, London Regional Cancer Program, Western University

R Gabriel. Boldt

London Health Sciences Centre

Alexander V. Louie

Department of Radiation Oncology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, CA; Department of Radiation Oncology, London Regional Cancer Program, London, Ontario, CA

Glenn Bauman

Department of Radiation Oncology, London Regional Cancer Program, London Health Sciences Centre, London, ON, CANADA, London, CAN


PDF Share
Converted f3f73e70995b11e79b96cdc8d5cb9072 meningioma poster